The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.

Q: I used to be a serious exerciser, but now that I am in my late 60s, I find it harder and harder to stay on track. Got any words ...

Do you have high cholesterol? You're not alone — millions of adults in the United States face this common but serious issue. High cholesterol increases the risk of heart disease, ...

High cholesterol can be reduced by eating certain foods. A British Heart Foundation cardiologist has shared the two foods ...

In recent study, 23 percent of NHANES primary prevention cohort currently using lipid-lowering therapies versus 47 percent eligible under U.S. guidelines.

Heart disease is often seen as a problem that only affects older adults, but more and more young people are being diagnosed ...

Switching what’s on your plate might change your cholesterol faster than you think—here’s what the latest research and ...

An experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific ...

Eli Lilly & Co. has divulged relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of diabetes, stroke, atherosclerosis, pulmonary hypertension, chronic obstructive ...

Dinesh Gundu Rao said more people were coming to hospitals for check-ups. At Jayadeva Institute of Cardiovascular Sciences, ...

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.

Zodasiran targets ANGPLT3, an emerging therapeutic target to treat HoFH and other dyslipidemias – YOSEMITE Phase 3 study further enhances Arrowhead’s late-stage pipeline o ...